Evidence map›Paper›PMID 34561691›Full record

ReviewNature protocols2021

A practical guide to large-scale docking.

Brian J Bender, Stefan Gahbauer, Andreas Luttens, Jiankun Lyu, Chase M Webb, Reed M Stein, Elissa A Fink, Trent E Balius, Jens Carlsson, John J Irwin and 1 more

Erratum issuedAbstract readReview
In one paragraph

Review in Nature protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 301 papers.

0numbers the graph read from it
0cells of the map it votes in
301citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

301 citing papers in PubMed.

  1. (+)-Trans-Cannabidiol Is an Agonist at Human CBPharmacology research & perspectives · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Robots and Minimal, Physics-Informed Features: A Hybrid Framework for Enzyme Catalysis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Machine Learning for RNA-Targeting Drug Design.Journal of chemical information and modeling · 2026
    Review
  17. Article
  18. Article
  19. Article
  20. Article

241 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Brian J Bender *Department of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.
Stefan Gahbauer *Department of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3115-9757
Andreas LuttensScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-2915-7901
Jiankun LyuDepartment of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.
Chase M WebbDepartment of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.
Reed M SteinDepartment of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.
Elissa A FinkDepartment of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.
Trent E BaliusNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-6811-4667
Jens CarlssonScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
John J IrwinDepartment of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, CA, USA. bshoichet@gmail.com.

Funding

Illuminating the Druggable GPCR-omeU24DK116195 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2017 to 2022
$14.3M
STRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1M
Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Molecular Details of Psychoactive Drug ActionsR01MH112205 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2017 to 2026
$6.1M
Mechanistic insights into LSD actions at 5-HT2A serotonin receptorsR37DA045657 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth · 2018 to 2026
$5.8M
Ultra-large library docking for ligand discoveryR01GM133836 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IRWIN, JOHN J. · 2019 to 2022
$1.6M
Advancing Homology Models to Identify Compounds for Understudied GPCRsF32GM136062 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BENDER, BRIAN J · 2020 to 2021
$131k
NIDA NIH HHS R37 DA045657NIDDK NIH HHS U24 DK116195NIGMS NIH HHS F32 GM136062NIGMS NIH HHS R01 GM133836NIGMS NIH HHS R35 GM122481NIGMS NIH HHS T32 GM007175NIGMS NIH HHS T32 GM008284NIMH NIH HHS R01 MH112205
6 · The paper itself

Abstract

Structure-based docking screens of large compound libraries have become common in early drug and probe discovery. As computer efficiency has improved and compound libraries have grown, the ability to screen hundreds of millions, and even billions, of compounds has become feasible for modest-sized computer clusters. This allows the rapid and cost-effective exploration and categorization of vast chemical space into a subset enriched with potential hits for a given target. To accomplish this goal at speed, approximations are used that result in undersampling of possible configurations and inaccurate predictions of absolute binding energies. Accordingly, it is important to establish controls, as are common in other fields, to enhance the likelihood of success in spite of these challenges. Here we outline best practices and control docking calculations that help evaluate docking parameters for a given target prior to undertaking a large-scale prospective screen, with exemplification in one particular target, the melatonin receptor, where following this procedure led to direct docking hits with activities in the subnanomolar range. Additional controls are suggested to ensure specific activity for experimentally validated hit compounds. These guidelines should be useful regardless of the docking software used. Docking software described in the outlined protocol (DOCK3.7) is made freely available for academic research to explore new hits for a range of targets.

Indexed as

Molecular Docking SimulationSoftwareDrug Discovery

Identifiers

PMID34561691
PMCPMC8522653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.